NTRK1 and non-small cell lung carcinoma: Anlotinib (AL3818) is a new multi-targeted receptor tyrosine kinase inhibitor (TKI) that is approved for treating advanced non-small cell lung cancer (NSCLC) in patients after more than two series of systematic chemotherapy5.